The prevalence of overweight or obese individuals worldwide has doubled since 1990. This rise in obesity has significantly impacted metabolic health resulting in the increase of non-communicable diseases such as cardiovascular disease, diabetes and cancer, predicted to cost more than $4 trillion by 2035. Although, metformin and GLP-1 agonists have revolutionized treatments in the clinic they are not without side effects. This session will highlight alternative approaches for the treatment of metabolic disease and highlight novel targets for exploitation. This encompasses a number of exciting avenues ranging from understudied orphan G-protein-coupled receptors through to second messengers and kinases.